Document is current
Any future updates will be listed below
-
Authors
Zott, Benedikt http://orcid.org/0000-0003-4537-7381
Nästle, Lea
Grienberger, Christine http://orcid.org/0000-0002-7774-4062
Unger, Felix http://orcid.org/0000-0003-0026-8026
Knauer, Manuel M. http://orcid.org/0000-0002-3475-2396
Wolf, Christian http://orcid.org/0009-0000-7755-4691
Keskin-Dargin, Aylin
Feuerbach, Anna
Busche, Marc Aurel http://orcid.org/0000-0002-4416-7553
Skerra, Arne http://orcid.org/0000-0002-5717-498X
Konnerth, Arthur http://orcid.org/0000-0002-9548-2676
-
Funding
Funding for this research was provided by:
Deutsche Forschungsgemeinschaft (685472)
Bundesministerium für Bildung und Forschung (n/a)
- License Information
-
More Information
Article History
Received: 25 January 2023
Accepted: 2 July 2024
First Online: 10 July 2024
Competing interests
: A.S. is founder and shareholder of Pieris Pharmaceuticals, Inc. Anticalin® is a registered trademark of Pieris Pharmaceuticals GmbH, Germany. All other authors declare no competing interests.
